Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Releases Earnings Results, Misses Estimates By $0.05 EPS

Posted by George Bondi on Oct 29th, 2026

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) announced its quarterly earnings results on Thursday. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05), Zacks reports. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.4%

Shares of OTCMKTS SGIOY traded down $0.04 during trading hours on Thursday, hitting $9.39. 32,289 shares of the stock were exchanged, compared to its average volume of 135,252. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01. The company has a market cap of $15.98 billion, a PE ratio of 9.39, a PEG ratio of 3.45 and a beta of 0.08. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $7.83 and a 12 month high of $12.00. The firm has a fifty day moving average price of $9.17 and a 200-day moving average price of $9.64.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. Three research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, the company has an average rating of “Strong Buy”.

Check Out Our Latest Stock Report on Shionogi & Co., Ltd. Unsponsored ADR

About Shionogi & Co., Ltd. Unsponsored ADR

(Get Free Report)

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.